Many people with type 2 diabetes can manage their blood sugar levels with lifestyle changes, including exercise and nutrition ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...

The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used ...

Recent pharmaceutical innovations have opened a new path for weight loss through drugs based on gut hormones such as GLP-1 ...